Solventum Corp Files 8-K: Other Events & Financials

TL;DR

Solventum Corp (spun from 3M) filed an 8-K on Aug 15th covering events from Aug 13th. Standard disclosure stuff.

AI Summary

Solventum Corporation, formerly 3M Health Care Co., filed an 8-K on August 15, 2025, reporting on events as of August 13, 2025. The filing primarily concerns "Other Events" and includes "Financial Statements and Exhibits." Solventum Corporation is incorporated in Delaware and its principal executive offices are located at 3M Center, Building 275-6W, St. Paul, MN.

Why It Matters

This 8-K filing provides official updates and disclosures from Solventum Corporation, which is crucial for investors and stakeholders to understand the company's current status and any significant events.

Risk Assessment

Risk Level: low — This filing appears to be a routine disclosure of events and financial statements, not indicating any immediate or significant risks.

Key Numbers

• 001-41968 — SEC File Number (Identifies the company's filing with the SEC)
• 92-2008841 — IRS Employer Identification No. (Tax identification number for the company)

Key Players & Entities

• Solventum Corporation (company) — Registrant
• 3M Health Care Co. (company) — Former name
• 3M Company (company) — Related entity for business and mail address
• August 13, 2025 (date) — Earliest event reported
• August 15, 2025 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• St. Paul, MN (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value SOLV New York Stock Excha

Filing Documents

• ef20054041_8k.htm (8-K) — 29KB
• ef20054041_ex1-1.htm (EX-1.1) — 186KB
• ef20054041_ex5-1.htm (EX-5.1) — 17KB
• ef20054041_ex99-1.htm (EX-99.1) — 13KB
• image00003.jpg (GRAPHIC) — 48KB
• image00004.jpg (GRAPHIC) — 3KB
• image00005.jpg (GRAPHIC) — 8KB
• 0001140361-25-031512.txt ( ) — 505KB
• solv-20250813.xsd (EX-101.SCH) — 4KB
• solv-20250813_lab.xml (EX-101.LAB) — 21KB
• solv-20250813_pre.xml (EX-101.PRE) — 16KB
• ef20054041_8k_htm.xml (XML) — 4KB

01

Item 8.01. Other Events. Underwriting Agreement On August 13, 2025, Solventum Corporation (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") by and among the Company, Goldman Sachs & Co. LLC and BofA Securities, Inc., as underwriters (the "Underwriters"), and 3M Company (the "Selling Shareholder"). The Underwriting Agreement relates to the sale of 8,800,000 shares (the "Shares") of the Company's common stock, par value $0.01 per share, by the Selling Shareholder, subject to and upon the terms and conditions set forth therein. On August 15, 2025, the Selling Shareholder sold the Shares to the Underwriters pursuant to the Underwriting Agreement. The offering of the Shares was registered under the Securities Act of 1933, as amended, pursuant to the Company's registration statement on Form S-3 (File No. 333-289578), which became automatically effective upon filing with the Securities and Exchange Commission. The Company did not issue or sell any shares of its common stock in that transaction and will not receive any proceeds from the sale of the Shares by the Selling Shareholder. The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the Underwriting Agreement, which is filed herewith as Exhibit 1.1 and is incorporated herein by reference. The opinion of Cleary Gottlieb Steen & Hamilton LLP, relating to the validity of the Shares, is filed as Exhibit 5.1 hereto. Press Release On August 13, 2025, the Company issued a press release announcing the pricing of the offering of the Shares. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated into this Item 8.01 by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 1.1 Underwriting Agreement, dated August 13, 2025, by and among Solventum Corporation, Goldman Sachs & Co. LLC, BofA Securities, Inc. and 3M Company. 5.1 Opinion of Cleary Gottlieb Steen & Hamilton LLP. 23.1 Consent of Cleary Gottlieb Steen & Hamilton LLP (included as part of Exhibit 5.1). 99.1 Press release announcing the pricing of the offering of the Shares, dated August 13, 2025. 104 Cover page interactive data file (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 15, 2025 Solventum Corporation By: /s/ Wayde McMillan Name: Wayde McMillan Title: Executive Vice President & Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR